SEARCH

SEARCH BY CITATION

References

  • 1
    Stenvinkel P, Chung SH, Heimburger O, Lindholm B. Malnutrition, inflammation and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 2001;21(Suppl. 3):15762.
  • 2
    Wanner C, Zimmerman J, Shwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int 2002;61:99102.
  • 3
    Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin-6-174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003;64:61622.
  • 4
    Takahashi H, Ishii H, Aoyama T et al. Association of cardiac valvular calcifications and c-reactive protein with cardiovascular mortality in incident hemodialysis patients: A Japanese cohort study. Am J Kidney Dis 2013;61:25461.
  • 5
    Yudkin JS, Kumari M, Humphries SE, Mohammed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:20914.
  • 6
    Hultgren O, Hahn-Zoric M, Andersson B, Almroth G. Interleukin 18 is up-regulated in ANCA-associated vasculitis. Autoimmunity 2007;40:52931.
  • 7
    Lönn J, Almroth G, Brudin L, Nayeri F. An Antithrombin III product containing biologically active hepatocyte growth factor may be beneficial in deep ulcer infections. Cytokine 2012;60:47886.
  • 8
    Lönn J, Starkhammar Johansson C, Kälvegren H et al. Hepatocyte growth factor in patients with coronary artery disease and its relation to periodontal condition. Results Immunol 2012;2:712.
  • 9
    Lönn J, Starkhammar JC, Sridhar S, Bengtsson T, Nayeri F, Ravald N. High concentrations of hepatocyte growth factor but low biological activity in patients with periodontitis. J Periodontol 2013. [Epub a head of print].
  • 10
    Lönn J, Shahzad F, Uhlin F, Bengtsson T, Almroth G, Nayeri F. High concentration but low biological activity of hepatocyte growth factor in patients with chronic renal failure. Adv Biosci Biotechnol 2012;3:51623.
  • 11
    Larsson TE. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant 2010;25:137681.
  • 12
    Faul C, Amarai AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393408.
  • 13
    Andia-Cannata JB, Roman-Garcia P, Hruska K. The connections between vascular calcification and bone health. Nephrol Dial Transplant 2011;26:342936.
  • 14
    Wang M, You L, Li H, Zhang Z, Hao C, Chen J. Association of Circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function. Clin J Am Soc Nephrol 2013;8:11625.
  • 15
    Viaene L, Bammens B, Meijers BK, Vanrenterghem Y, Vanderschueren D, Evenpoel P. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrol Dial Transplant 2012;27:201722.
  • 16
    Pawlak K, Ulazka B, Mysliwiec M, Pawlak D. Vascular endothelial growth factor and uPAR/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis? Transl Res 2012;160:34654. Epub 2012 May 8.
  • 17
    Lyngbaek S, Marott JL, Möller DV et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol 2012;110:15663.
  • 18
    Lee C-T, Ng H-Y, Hsu C-Y et al. Proinflammatory cytokines, hepatocyte growth factors and adipokines in peritoneal dialysis patients. Artif Organs 2010;34:2229.
  • 19
    Jean G, Bresson E, Lorriaux C et al. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. Nephron Clin pract 2012;120:1328.
  • 20
    Chitalia N, Afzali B, Edozie F et al. Serum FGF-23 is linked with increased inflammatory cytokines in CKD stage 3-5. Is this the explanation for its adverse CV effects? Abstract Am Soc Nephrol 2012, and European Renal Association (ERA EDTA); 2012, FP246.
  • 21
    Oliveira RB, Cancela ALE, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy. Clin J Am Soc Nephrol 2010;5:28691.
  • 22
    Chertow GM, Block GA, Correa-Rotter R et al. The effect of Cinacalcet on cardiovascular disease in patients undergoing dialysis. The Evolve trial investigators. N Engl J Med 2012;367:248294 (Dec 27).
  • 23
    Fernstrom A, Giaever J, Granroth B et al. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study. Scand J Urol Nephrol 2011;45:196205.
  • 24
    Jia T, Qureshi AR, Gross T et al. Determinants of FGF23 and PTH Variability in Dialysis Patients. Am J Nephrol 2013;37:46271.
  • 25
    Khan AM, Chirinos JA, Litt H, Yang W, Rosas SE. FGF-23 and the progression of coronary artery calcification in patients new to dialysis. Clin J Am Soc Nephrol 2012;7:201722.
  • 26
    Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:58492.
  • 27
    Trachtman H, Li J, Wei C et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012;23:20519.